182 related articles for article (PubMed ID: 29615462)
1. Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients.
Gordevičius J; Kriščiūnas A; Groot DE; Yip SM; Susic M; Kwan A; Kustra R; Joshua AM; Chi KN; Petronis A; Oh G
Clin Cancer Res; 2018 Jul; 24(14):3317-3324. PubMed ID: 29615462
[No Abstract] [Full Text] [Related]
2. Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France.
Houédé N; Beuzeboc P; Gourgou S; Tosi D; Moise L; Gravis G; Delva R; Fléchon A; Latorzeff I; Ferrero JM; Oudard S; Tartas S; Laguerre B; Topart D; Roubaud G; Agherbi H; Rebillard X; Azria D
BMC Cancer; 2015 Apr; 15():222. PubMed ID: 25884302
[TBL] [Abstract][Full Text] [Related]
3. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ
Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882
[TBL] [Abstract][Full Text] [Related]
4. Abiraterone acetate in the treatment of prostate cancer.
Thakur A; Roy A; Ghosh A; Chhabra M; Banerjee S
Biomed Pharmacother; 2018 May; 101():211-218. PubMed ID: 29494958
[TBL] [Abstract][Full Text] [Related]
5. Abiraterone acetate and its use in the treatment of metastatic prostate cancer: a review.
Caffo O; Veccia A; Kinspergher S; Maines F
Future Oncol; 2018 Feb; 14(5):431-442. PubMed ID: 29350549
[TBL] [Abstract][Full Text] [Related]
6. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW
Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060
[TBL] [Abstract][Full Text] [Related]
7. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.
Miller K; Carles J; Gschwend JE; Van Poppel H; Diels J; Brookman-May SD
Eur Urol; 2018 Jul; 74(1):17-23. PubMed ID: 28939004
[TBL] [Abstract][Full Text] [Related]
8. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
Tagawa ST; Posadas EM; Bruce J; Lim EA; Petrylak DP; Peng W; Kheoh T; Maul S; Smit JW; Gonzalez MD; De Porre P; Tran N; Nanus DM
Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075
[TBL] [Abstract][Full Text] [Related]
9. Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors.
Fan L; Dong B; Chi C; Wang Y; Gong Y; Sha J; Pan J; Shangguan X; Huang Y; Zhou L; Xue W
BMC Urol; 2018 Dec; 18(1):110. PubMed ID: 30509237
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of the cell-free DNA methylome of metastatic prostate cancer during androgen-targeting treatment.
Peter MR; Bilenky M; Isserlin R; Bader GD; Shen SY; De Carvalho DD; Hansen AR; Hu P; Fleshner NE; Joshua AM; Hirst M; Bapat B
Epigenomics; 2020 Aug; 12(15):1317-1332. PubMed ID: 32867540
[No Abstract] [Full Text] [Related]
11. Germline Variant in HSD3B1 (1245 A > C) and Response to Abiraterone Acetate Plus Prednisone in Men With New-Onset Metastatic Castration-Resistant Prostate Cancer.
Hahn AW; Gill DM; Nussenzveig RH; Poole A; Farnham J; Cannon-Albright L; Agarwal N
Clin Genitourin Cancer; 2018 Aug; 16(4):288-292. PubMed ID: 29674118
[TBL] [Abstract][Full Text] [Related]
12. Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer.
Scott LJ
Drugs; 2017 Sep; 77(14):1565-1576. PubMed ID: 28819727
[TBL] [Abstract][Full Text] [Related]
13. Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction.
Cindolo L; Natoli C; De Nunzio C; De Tursi M; Valeriani M; Giacinti S; Micali S; Rizzo M; Bianchi G; Martorana E; Scarcia M; Ludovico GM; Bove P; Laudisi A; Selvaggio O; Carrieri G; Bada M; Castellan P; Topazio L; Boccasile S; Ditonno P; Chiodini P; Schips L
Clin Genitourin Cancer; 2017 Oct; 15(5):520-525. PubMed ID: 28478884
[TBL] [Abstract][Full Text] [Related]
14. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
Bellmunt J; Kheoh T; Yu MK; Smith MR; Small EJ; Mulders PF; Fizazi K; Rathkopf DE; Saad F; Scher HI; Taplin ME; Davis ID; Schrijvers D; Protheroe A; Molina A; De Porre P; Griffin TW; de Bono JS; Ryan CJ; Oudard S
Eur Urol; 2016 May; 69(5):924-32. PubMed ID: 26508309
[TBL] [Abstract][Full Text] [Related]
15. A drug safety evaluation of abiraterone acetate in the treatment of prostate cancer.
Castellan P; Castellucci R; Marchioni M; De Nunzio C; Tema G; Primiceri G; Schips L; Cindolo L
Expert Opin Drug Saf; 2019 Sep; 18(9):759-767. PubMed ID: 31353982
[No Abstract] [Full Text] [Related]
16. Counterpoint: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate Cancer: The Case for Abiraterone.
Jones RJ
Oncology (Williston Park); 2018 May; 32(5):223, 226-7, 247. PubMed ID: 29847852
[No Abstract] [Full Text] [Related]
17. Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate-Treated Castration-Resistant Prostate Cancer Patients.
Xu XS; Ryan CJ; Stuyckens K; Smith MR; Saad F; Griffin TW; Park YC; Yu MK; Vermeulen A; Poggesi I; Nandy P
Clin Cancer Res; 2015 Jul; 21(14):3170-7. PubMed ID: 25829400
[TBL] [Abstract][Full Text] [Related]
18. Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.
Massoudi M; Balk M; Yang H; Bui CN; Pandya BJ; Guo J; Song Y; Wu EQ; Brown B; Barlev A; Flanders S
J Med Econ; 2017 Feb; 20(2):121-128. PubMed ID: 27570999
[TBL] [Abstract][Full Text] [Related]
19. Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate.
Giacinti S; Carlini P; Roberto M; Bassanelli M; Strigari L; Pavese F; Aschelter AM; Felici A; Valeriani M; Cognetti F; Marchetti P
Anticancer Drugs; 2017 Jan; 28(1):110-115. PubMed ID: 27763885
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients: a prospective evaluation.
Prati V; Ruatta F; Aversa C; Gernone A; Galizia D; Bonzano A; Torino S; Nuzzolese I; Marandino L; Aglietta M; Ortega C
Future Oncol; 2018 Feb; 14(5):443-448. PubMed ID: 29318908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]